ALK and anaplastic large cell lymphoma: A recent trial reported that the addition of etoposide to CHOP improved event-free survival in young patients with ALK-positive anaplastic large cell lymphomas (event-free survival at 3 years 91.2% versus 57.1%, P = .012), but the overall survival was not significantly different.